Endomagnetics is pleased to announce it has reached an agreement with Aurora BioScience as its exclusive distributor for Australia and New Zealand. This appointment extensively extends the availability of the company’s SentiMag® and Sienna+® tracer system. Breast cancer patients in the region will now have access to new technology that optimally locates lymph nodes as part of the cancer staging method in Sentinel Lymph Node Biopsy (SLNB).
recent standard-of-care for SLNB requires a radioactive isotope injection, which has limited availability in Australia and New Zealand. The SentiMag system increases the availability of the standard-of-care and also improves workflow, putting the surgeon in control of tracer injection. The system has been used in 10 clinical studies and trials with over 1,500 patients across 12 European countries since 2012. The first two trials have published recently, and demonstrated clinical similarity to the standard-of-care.
Aurora Bioscience is exclusively responsible for the sales, marketing and distribution of the SentiMag system in the Australian and New Zealand markets. Aurora is a leading specialist distributor of high technology medical devices across fields including oncology, blood technology, respiratory medicine and neurology. It provides a service to metropolitan and regional areas across Australia and New Zealand and around the Pacific Islands.
Mathew Stephens, Director of Sales and Business Development at Endomagnetics said: “We are delighted to be working with the team at Aurora as this appointment significantly strengthens our distribution in this key geographical market. The interest from Australian and New Zealand surgeons has been gigantic and we are looking forward to developments in the coming months.”
For Aurora BioScience, Darren Banks, Managing Director said: “The Endomagnetics technology is a perfect fit with our advanced, inventive range of medical devices, and the technology will significantly improve patient experience by extending availability of the SLNB technique”.